Skip to main content

Table 1 Baseline clinical characteristics

From: The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome

  Statin group (n = 52) Combination group (n = 52) p
AMI/ UA (n) 27/25 30/22 0.144
Gender (male/female) 16/36 20/32 0.101
Age (years) 60 ± 6 59 ± 8 0.356
Body mass index (kg/m2) 23.48 ± 1.67 23.94 ± 2.09 0.233
Systolic blood pressure (mmHg) 131 ± 11 133 ± 12 0.195
Diastolic blood pressure (mmHg) 76 ± 8 75 ± 9 0.471
Fasting blood glucose (mmol/L) 5.45 ± 0.66 5.62 ± 0.95 0.263
ALT (u/L) 31.57 ± 21.06 29.08 ± 16.67 0.688
Cr (μmol/L) 87.4 ± 21.67 86.03 ± 18.84 0.728
CK (u/L) 86.01 ± 22.91 87.13 ± 46.38 0.875
TG (mmol/L) 1.97 ± 1.02 1.91 ± 0.87 0.740
TC (mmol/L) 4.85 ± 0.90 4.92 ± 0.83 0.644
LDL-C (mmol/L) 3.00 ± 0.43 3.04 ± 0.46 0.686
HDL-C (mmol/L) 0.89 ± 0.22 0.93 ± 0.14 0.317
Apo A5 (ng/ml) 49.49 ± 1.59 49.50 ± 2.48 0.980
hs-CRP (mg/L) 3.97 ± 3.52 3.89 ± 2.96 0.904
  1. Note: AMI acute myocardial infarction, UA unstable angina, ALT alanine aminotransferase, Cr creatinine, CK creatine kinase, TG triglycerides, TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, ApoA5 apolipoprotein A5, hs-CRP high-sensitivity C-reactive protein.